Decongestion Guided By VExUS Score Or Lung Ultrasound For Renal Recovery In Patients With Cardiorenal Syndrome Type -1

NCT06786728 | Enrolling By Invitation

• 1 other identifier: MD8.1.2024
• Study Type: interventional
• Target: 146
• Locations: 1 country
• Sites: 1

Brief Summary

the goal of this observational study is to evaluate the role of VEXUS score and lung ultrasound to guide decongestive therapy in patients with cardiorenal syndrome type -1. the main question it aims to answer is: Can the VEXUS score and lung ultrasound guide the efffect of decongestive therapy on KFR and decongestion metrics in patients with CRS-1 compared to standard assesment ?

Conditions

Cardiorenal Syndrome Type 1

Outcome Measures

Primary Outcomes (1)

• assesment of KFR using the KDIGO AKI staging improvement

  stage1:serum creatinine increase 1,5 - 2 folds serum creatinine increase 2 - 3 folds serum creatinine increase more than 3 folds

  1 week

Secondary Outcomes (1)

• VEXUS score

  48 hours

Study Arms (2)

the VEXUS group :in this group we use the vexus score to guide decongestive theapy

ACTIVE COMPARATOR

the use of diuretic if vexus score more than 1 at time of enrollement

Drug: frusemide

the lung US group : we use lung ultrasound score to detect degree of pulmonary congestion

ACTIVE COMPARATOR

if lung ultrasound score more than 15 we will start diuretic therapy

Drug: frusemide

Interventions

frusemide DRUG

in this group we use vexus score to asses decongestion in comparison to lung ultrasound in other group

the VEXUS group :in this group we use the vexus score to guide decongestive theapy; the lung US group : we use lung ultrasound score to detect degree of pulmonary congestion

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients of both genders aged 18-65 years old.
• Patients with CRS1 criteria (worsening of renal function due to acute heart failure manifested by : ( Dyspnea , orthopnea ,hypoxia , congested neck veins , oliguria and congestion in imaging.)
• Patients with Modified lung ultrasound score(LUSS) more than 15.

You may not qualify if:

• Refusal to participate.
• Patients with renal transplantation.
• Unknowing baseline creatinine.
• Patients with a life-threatening indication of RRT (defined as intractable hyperkalemia, acidosis, uremic symptoms) at enrollment,
• RRT before recruitment,
• known prehospitalization advanced chronic kidney disease (defined by an estimated GFR \<30 mL/min/1.73 m2 or chronic RRT),
• use of extracorporeal membrane oxygenation (ECMO),
• diagnosis of hepatic cirrhosis or other condition with portal hypertension
• Or postrenal causes of AKI

Sponsors & Collaborators

• Benha University: lead

Study Sites (1)

Asmaa Shahat Mohamedy Behairy

Cairo, Egypt

Location

MeSH Terms

Interventions

Furosemide

Intervention Hierarchy (Ancestors)

Sulfanilamides; Sulfonamides; Amides; Organic Chemicals; Aniline Compounds; Amines; Sulfones; Sulfur Compounds

Study Officials

• asmaa AS Behairy, master

  Benha University

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Benha University

Study Record Dates

• First Submitted: December 5, 2024
• First Posted: January 22, 2025
• Study Start: August 10, 2024
• Primary Completion: July 1, 2025
• Study Completion: August 1, 2025
• Last Updated: January 22, 2025

Record last verified: 2025-01

Data Sharing

• IPD Sharing: Will not share

Locations

EG (1)